title: Drug-induced interstitial pneumonitis due to low-dose lenalidomide.
abstract: Lenalidomide is a second-generation immunomodulatory drug that has been approved to treat relapsed or refractory multiple myeloma. Here, we describe a patient who was treated with a low dose of lenalidomide (5 mg/day on days 1-21 of a 28-day cycle) because the standard dose of bortezomib was too toxic and adverse events persisted. However, he developed fever, dyspnea, hypoxia and pulmonary infiltrates. The results of an extensive workup for other causes including infections were negative and the final diagnosis was lenalidomide-induced interstitial pneumonitis. This is the first case report of lenalidomide-induced pneumonitis in a Japanese patient.
authors.affiliation: Department of Respiratory Medicine, Kurashiki Central Hospital, Japan. kk11900@kchnet.or.jp
authors.forename: Kei
authors.initials: K
authors.lastname: Kunimasa
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Ueda
authors.forename: Machiko
authors.initials: M
authors.lastname: Arita
authors.forename: Takeshi
authors.initials: T
authors.lastname: Maeda
authors.forename: Machiko
authors.initials: M
authors.lastname: Hotta
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ishida
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D000077269:Lenalidomide; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis*; D008297:Male; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide